Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma

Cerenome completed enrollment in its Phase 2 ReSPECT-GBM study, with topline data expected in mid-2027. Previously reported interim data showed median overall survival of 13 months versus 8 months with standard of care in recurrent glioblastoma, a 63% improvement; this is not the topline result from the completed study.

Analysis

Enrollment completion reduces the risk of further recruitment delays, but it does not validate the interim survival signal or establish commercial value. The 13-versus-8-month comparison is potentially meaningful in recurrent glioblastoma, yet the investment case hinges on trial size, randomization, follow-up maturity, statistical confidence, treatment-arm balance, and whether the comparator reflects current practice. Those details are not provided; the interim result should therefore be treated as a hypothesis, not a reliable estimate of eventual benefit.

The key near-term effect is likely a lower enrollment-execution discount, offset by a long period of binary readout risk. With topline expected in mid-2027, the next 1–3 months matter mainly for protocol, follow-up, and funding disclosures—not efficacy resolution. Over 6–18 months, a positive controlled result could materially improve CNSY’s partnering and financing leverage; a weak or inconsistent result could sharply impair the asset’s value. The announcement alone does not establish CNSY’s cash runway or whether financing will be needed before readout.

Contrarian angle: the headline survival comparison may anchor investors too strongly. In a small interim dataset, a striking median difference can narrow or disappear with fuller follow-up; conversely, successful enrollment removes one genuine operational risk. No defensible valuation or price target is possible without trial details, current cash/runway, and the market’s implied probability of success.

Key Decisions for Investors

• Do not chase CNSY solely on enrollment completion or the interim median-survival comparison. Treat this as a modest execution de-risking event, not confirmation of efficacy.
• Keep CNSY on a catalyst watchlist and verify trial size, randomization, confidence intervals, follow-up maturity, comparator regimen, and the company’s cash runway in filings or conference materials before sizing a position.
• If holding CNSY, cap exposure to an event-risk position that can tolerate a substantial loss; avoid adding ahead of the mid-2027 readout unless new, independently assessable evidence changes the probability of success.
• Reassess the thesis if the company discloses materially immature or imbalanced interim data, delays the topline timeline, signals financing needs before readout, or reports later survival results that fail to preserve a credible advantage over the control arm.